Table 1.

Clinical evidence in support of the World Health Organization’s Option A and Option B approaches for the prevention of mother-to-child HIV transmission among women who are yet ineligible for antiretroviral therapy

	Option A		Option B
	Mother	Infant	Mother	Infant
Antenatal	ZDV from 14 onward [10–12]	–	Three-drug combination antiretroviral regimen from 14 weeks until breastfeeding cessation [13–16]	-
Intrapartum	Single-dose NVP and 1-week ZDV+3TC [5, 17, 18]	–		-
Postpartum	–	NVP for 6 weeks or until the end of breastfeeding [13, 19–21]		NVP or ZDV for 6 weeks [19]

ZDV = zidovudine; 3TC = lamivudine; NVP = nevirapine